This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiehl, M. G. Articles by Ringden, O. Search for Related Content PubMed PubMed Citation Articles by Kiehl, M. G. Articles by Ringden, O.

Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission

From the Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein; German Clinic for Diagnostics, Wiesbaden; Medizinische Hochschule, Hannover; University Hospital Eppendorf, Hamburg; Westfaelische Wilhelms University, Muenster; Carl Gustav Carus University, Dresden; University Hospital, Frankfurt; University Hospital, Cologne, Germany; Center for Allogeneic Stem Cell Transplantation, Huddinge, Sweden

Address reprint requests to Michael G. Kiehl, MD, Clinic for Bone Marrow Transplantation and Hematology/Oncology, Dr-Ottmar-Kohler-Str 2, 55743 Idar-Oberstein, Germany; e-mail: mkiehl{at}bmt-center-io.com

PURPOSE: The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors.

PATIENTS AND METHODS: The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen–identical related (n = 103), or matched unrelated (n = 118) donor.

RESULTS: Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P = .014) or who relapsed (P < .001). We observed a clear trend toward improved survival in favor of B-lineage ALL patients compared with T-lineage ALL patients (P = .052), and Philadelphia chromosome–positive patients had no poorer outcome than Philadelphia chromosome–negative patients. Total-body irradiation–based conditioning improved DFS in comparison with busulfan (P = .041).

CONCLUSION: Myeloablative matched related or matched unrelated allogeneic hematopoietic stem-cell transplantation in ALL patients should be performed in first CR.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				J. M. Rowe Allografting in ALL: the net widens Blood, July 15, 2008; 112(2): 212 - 212. [Full Text] [PDF]

				D. I. Marks, W. S. Perez, W. He, M.-J. Zhang, M. R. Bishop, B. J. Bolwell, C. N. Bredeson, E. A. Copelan, R. P. Gale, V. Gupta, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission Blood, July 15, 2008; 112(2): 426 - 434. [Abstract] [Full Text] [PDF]

				A. H. Goldstone, S. M. Richards, H. M. Lazarus, M. S. Tallman, G. Buck, A. K. Fielding, A. K. Burnett, R. Chopra, P. H. Wiernik, L. Foroni, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood, February 15, 2008; 111(4): 1827 - 1833. [Abstract] [Full Text] [PDF]

				N. S. Fox, F. A. Chervenak, and L. B. McCullough Ethical Considerations in Umbilical Cord Blood Banking Obstet. Gynecol., January 1, 2008; 111(1): 178 - 182. [Abstract] [Full Text] [PDF]

				J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF]

				H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF]

				P. O. Iversen, D. R. Sorensen, K. J. Tronstad, O. A. Gudbrandsen, A. C. Rustan, R. K. Berge, and C. A. Drevon A bioactively modified Fatty Acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3525 - 3531. [Abstract] [Full Text] [PDF]

				M. Stelljes, M. Bornhauser, M. Kroger, J. Beyer, M. C. Sauerland, A. Heinecke, B. Berning, C. Scheffold, G. Silling, T. Buchner, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Blood, November 1, 2005; 106(9): 3314 - 3321. [Abstract] [Full Text] [PDF]